title: Treatment of splenic marginal zone lymphoma.
abstract: Splenic marginal zone lymphoma (SMZL) is a distinct lymphoma entity characterized by an indolent clinical course and prolonged survival. Treatment is not standardized, since there are no prospective randomized trials in large series of SMZL patients. Splenectomy and rituximab represent the most effective treatment strategies used so far. The addition of chemotherapy to rituximab has not further improved the outcome, although this issue requires further investigation. Rituximab monotherapy has been associated with high response rates (∼90%), with approximately half of these responses being complete, even at the molecular level. More importantly, many of these responses are long-lasting, with a reported 7-year progression-free survival (PFS) at the rate of 69%. Maintenance rituximab treatment has been associated with further improvement of the quality of response as well as longer response duration in studies derived from one group of investigators. Based on its high efficacy and the good safety profile, rituximab represent one of the best treatment options for SMZL patients. Moreover, rituximab retains its efficacy in the relapse setting in most cases. Splenectomy is a meaningful alternative to rituximab in patients with bulky splenomegaly and cytopenias, without extensive bone marrow infiltration, who are fit for surgery. However splenectomy cannot completely eradicate the disease and it is also associated with greater morbidity or even mortality compared to rituximab. The choice of one of these two treatment approaches (rituximab or splenectomy) should mainly be based on patient's characteristics and on the disease burden. Novel agents are currently testing in low grade lymphomas including a small number of SMZL patients with promising results.
authors.affiliation: Department of Haematology, Heraklion University Hospital, 71001, University of Crete, Heraklion, Crete, Greece. Electronic address: xkalpadaki@yahoo.gr.
authors.forename: Christina
authors.initials: C
authors.lastname: Kalpadakis
authors.affiliation: Department of Haematology, Athens Medical Center-Psychikon Branch, 11525, Athens, Greece. Electronic address: pangalis@med.uoa.gr.
authors.forename: Gerassimos A
authors.initials: GA
authors.lastname: Pangalis
authors.affiliation: Department of Haematology, National and Kapodistrian University, Laikon General Hospital, Athens, Greece. Electronic address: mkangelop@gmail.com.
authors.forename: Maria K
authors.initials: MK
authors.lastname: Angelopoulou
authors.affiliation: Department of Haematology, National and Kapodistrian University, Laikon General Hospital, Athens, Greece. Electronic address: tvassilak@med.uoa.gr.
authors.forename: Theodoros P
authors.initials: TP
authors.lastname: Vassilakopoulos
mesh_terms: D018572:Disease-Free Survival; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D000069283:Rituximab / Q000627:therapeutic use*; D013156:Splenectomy; D013160:Splenic Neoplasms; D015996:Survival Rate
chemical_list: D000069283:Rituximab
keywords: Rituximab; Splenectomy; Splenic marginal zone lymphoma; Treatment